Denosumab biosimilar - AryoGen Pharmed

Drug Profile

Denosumab biosimilar - AryoGen Pharmed

Latest Information Update: 17 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AryoGen Pharmed
  • Class Antineoplastics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Postmenopausal osteoporosis

Most Recent Events

  • 12 Mar 2017 Preclinical trials in Postmenopausal osteoporosis in Iran (SC) before March 2017 (IRCT2017020521315N9)
  • 12 Mar 2017 AryoGen Pharmed plans a phase III trial for Postmenopausal osteoporosis in Iran (SC, Injection) (IRCT2017020521315N9)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top